Geetha A Subramaniam1, Maxine A Stitzer2, Philip Clemmey2, Ken Kolodner2, Marc J Fishman2. 1. Drs. Subramaniam, Stitzer, and Fishman (part-time) are with the Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore; Drs. Subramaniam and Fishman are also with Mountain Manor Treatment Center, Baltimore; and Dr. Kolodner is a private statistical consultant in Baltimore. At the time of the study, Dr. Clemmey was with Mountain Manor Treatment Center; he is now with St. Luke's-Roosevelt Hospital, New York.. Electronic address: gsubram@jhmi.edu. 2. Drs. Subramaniam, Stitzer, and Fishman (part-time) are with the Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore; Drs. Subramaniam and Fishman are also with Mountain Manor Treatment Center, Baltimore; and Dr. Kolodner is a private statistical consultant in Baltimore. At the time of the study, Dr. Clemmey was with Mountain Manor Treatment Center; he is now with St. Luke's-Roosevelt Hospital, New York.
Abstract
OBJECTIVE: To characterize baseline depressive symptoms among substance-abusing adolescents and determine their association with post residential treatment substance use outcomes. METHOD: In total, 153 adolescents (mean age 6.6 years, +/- 0.11) entering residential treatment were assessed at intake and at 3, 6, 9, and 12 months. Beck Depression Inventory (BDI) and Global Appraisal of Individual Needs were administered to assess depression, other risk factors, and substance use. A regression model was developed with 10 risk factors including BDI scores of >/=11 versus <11 to predict the outcome measure mean percentage of days in the past 90 days with any (nonnicotine) substance use. RESULTS: At intake, 55% had BDI scores of >/=11. A baseline BDI score of >/=11 was significantly associated with greater mean percentage of days of substance use (27.5 +/- 3.8% versus 15.4 +/- 4.0% days, p <.01) across 1-year follow-up. Two other factors were significant: length of drug career >2 years and having an opioid use disorder. CONCLUSIONS: Results from this prospective study, although preliminary, suggest the association of depressive symptoms with poorer substance outcomes and the utility of the BDI as a prognostic tool. They highlight the need for interventions targeting co-occurring depressive symptoms that may improve adolescent substance treatment outcomes.
OBJECTIVE: To characterize baseline depressive symptoms among substance-abusing adolescents and determine their association with post residential treatment substance use outcomes. METHOD: In total, 153 adolescents (mean age 6.6 years, +/- 0.11) entering residential treatment were assessed at intake and at 3, 6, 9, and 12 months. Beck Depression Inventory (BDI) and Global Appraisal of Individual Needs were administered to assess depression, other risk factors, and substance use. A regression model was developed with 10 risk factors including BDI scores of >/=11 versus <11 to predict the outcome measure mean percentage of days in the past 90 days with any (nonnicotine) substance use. RESULTS: At intake, 55% had BDI scores of >/=11. A baseline BDI score of >/=11 was significantly associated with greater mean percentage of days of substance use (27.5 +/- 3.8% versus 15.4 +/- 4.0% days, p <.01) across 1-year follow-up. Two other factors were significant: length of drug career >2 years and having an opioid use disorder. CONCLUSIONS: Results from this prospective study, although preliminary, suggest the association of depressive symptoms with poorer substance outcomes and the utility of the BDI as a prognostic tool. They highlight the need for interventions targeting co-occurring depressive symptoms that may improve adolescent substance treatment outcomes.
Authors: L A R Stein; Rebecca Lebeau; Suzanne M Colby; Nancy P Barnett; Charles Golembeske; Peter M Monti Journal: J Stud Alcohol Drugs Date: 2011-05 Impact factor: 2.582
Authors: Mary Clair-Michaud; Rosemarie A Martin; Linda A R Stein; Shayna Bassett; Rebecca Lebeau; Charles Golembeske Journal: J Subst Abuse Treat Date: 2015-09-25
Authors: Lina E Homman; Alexis C Edwards; Seung Bin Cho; Danielle M Dick; Kenneth S Kendler Journal: Subst Use Misuse Date: 2016-11-16 Impact factor: 2.164
Authors: L A R Stein; Mary Clair; Rebecca Lebeau; Suzanne M Colby; Nancy P Barnett; Charles Golembeske; Peter M Monti Journal: Drug Alcohol Depend Date: 2011-04-29 Impact factor: 4.492
Authors: Geetha A Subramaniam; Maxine L Stitzer; George Woody; Marc J Fishman; Ken Kolodner Journal: Drug Alcohol Depend Date: 2008-09-25 Impact factor: 4.492
Authors: Elina Sihvola; Richard J Rose; Danielle M Dick; Lea Pulkkinen; Mauri Marttunen; Jaakko Kaprio Journal: Addiction Date: 2008-10-08 Impact factor: 6.526
Authors: Richard A Brown; Ana M Abrantes; Haruka Minami; Mark A Prince; Erika Litvin Bloom; Timothy R Apodaca; David R Strong; Dawn M Picotte; Peter M Monti; Laura MacPherson; Stephen V Matsko; Jeffrey I Hunt Journal: J Subst Abuse Treat Date: 2015-07-03
Authors: Benjamin I Goldstein; Wael Shamseddeen; Anthony Spirito; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Benedetto Vitiello; Neal Ryan; Boris Birmaher; Taryn Mayes; Matthew Onorato; Jamie Zelazny; David A Brent Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-12 Impact factor: 8.829
Authors: Maria Orlando Edelen; Mary Ellen Slaughter; Daniel F McCaffrey; Kirsten Becker; Andrew R Morral Journal: Drug Alcohol Depend Date: 2009-10-09 Impact factor: 4.492